Albert Bourla, Pfizer CEO (Markus Schreiber/AP Images)
Pfizer cuts eight programs, including dwarfism drug at center of Therachon buyout
Pfizer is culling a number of programs in its pipeline, it disclosed in an update linked to its fourth quarter earnings call Tuesday.
Among those …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
